Stockscreener 앱 받기
4.21
2.18%
0.09
시간 외 거래:
4.21
Alpha Cognition Inc 주식(ACOG)의 최신 뉴스
Alpha Cognition Inc. Reports Strong 2024 Financials - TipRanks
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace
Alpha Cognition announces board changes - Investing.com Australia
Alpha Cognition announces board changes By Investing.com - Investing.com Canada
Alpha Cognition Appoints Robert Wills To Board - citybiz
Alpha Cognition Earnings Call: Positive Outlook Amid Growth - TipRanks
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - The Globe and Mail
Alpha Cognition stock hits 52-week low at $4.65 amid downturn - Investing.com Canada
HC Wainwright Expects Stronger Earnings for Alpha Cognition - Defense World
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 - TradingView
Alpha Cognition (NASDAQ:ACOG) Given Buy Rating at HC Wainwright - Defense World
Alpha Cognition Inc. (ACOG) reports earnings - Quartz
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - Business Wire
Earnings Scheduled For March 31, 2025 - Benzinga
Comparing Alpha Cognition (ACOG) and The Competition - Defense World
Alpha Cognition (NASDAQ:ACOG) Upgraded at Raymond James - Defense World
Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Alpha Cognition (ACOG) Projected to Release Quarterly Earnings on Wednesday - Defense World
HC Wainwright Predicts Alpha Cognition Q1 Earnings - MarketBeat
Rosalind Advisors Inc. Invests $1.49 Million in Alpha Cognition, Inc. (NASDAQ:ACOG) - MarketBeat
Alpha Cognition (NASDAQ:ACOG) Now Covered by HC Wainwright - MarketBeat
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - The Globe and Mail
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - Business Wire
90% Workforce Reduction Sent This Small Cap Soaring - The Globe and Mail
UNTHSC Names Permanent TCOM Dean and Alpha Cognition Commercializes Alzheimer's Drug - D Magazine
Alpha Cognition (NASDAQ:ACOG) Now Covered by Analysts at HC Wainwright - Defense World
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease - BioSpace
Alpha Cognition Launches Sales of Alzheimer’s Drug ZUNVEYL - dallasinnovates.com
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst - Benzinga
Alpha Cognition Inc.Common Stock (NQ: ACOG - FinancialContent
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL - The Globe and Mail
Alpha Cognition Launches Zunveyl for Treating Alzheimer's Disease; Shares Up Pre-Bell - Marketscreener.com
HC Wainwright Initiates Alpha Cognition at Buy With $20 Price Target -March 18, 2025 at 07:07 am EDT - Marketscreener.com
HC Wainwright & Co. Initiates Coverage of Alpha Cognition (ACOG) with Buy Recommendation - Nasdaq
H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy - TradingView
Acetylcholinesterase Inhibitors Market is expected to reach - openPR
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory - Insider Monkey
Alpha Cognition sets new executive and director compensation By Investing.com - Investing.com Australia
0.15%
4.32%
자본화:
|
볼륨(24시간):